{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:24:52Z","timestamp":1790835892138,"version":"4.1.0"},"reference-count":84,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1R01-DK-118942"],"award-info":[{"award-number":["1R01-DK-118942"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["5R21-DK-105401"],"award-info":[{"award-number":["5R21-DK-105401"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:p>Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors are the most recently approved class of diabetes drugs. Unlike other agents, SGLT2 inhibitors act on the kidney to promote urinary glucose excretion. SGLT2 inhibitors provide multiple benefits, including decreased HbA1c, body weight, and blood pressure. These drugs have received special attention because they decrease the risk of major adverse cardiovascular events and slow progression of diabetic kidney disease (1\u20133). Balanced against these impressive benefits, the U.S. Food and Drug Administration\u2013approved prescribing information describes a long list of side effects: genitourinary infections, ketoacidosis, bone fractures, amputations, acute kidney injury, perineal necrotizing fasciitis, and hyperkalemia. This review provides a physiological perspective to understanding the multiple actions of these drugs complemented by a clinical perspective toward balancing benefits and risks.<\/jats:p>","DOI":"10.2337\/dbi18-0006","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:34:16Z","timestamp":1558398856000},"page":"1109-1120","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":61,"title":["Sodium\u2013Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research"],"prefix":"10.2337","volume":"68","author":[{"given":"Amber L.","family":"Beitelshees","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Leslie","sequence":"additional","affiliation":[{"name":"Seventh Doctor Consulting, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-7854","authenticated-orcid":false,"given":"Simeon I.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,5,13]]},"reference":[{"key":"2022031303363917600_B1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031303363917600_B2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031303363917600_B3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031303363917600_B4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"2022031303363917600_B5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab"},{"key":"2022031303363917600_B6","doi-asserted-by":"crossref","first-page":"e10241","DOI":"10.1371\/journal.pone.0010241","article-title":"A single amino acid change converts the sugar sensor SGLT3 into a sugar transporter","volume":"5","author":"Bianchi","year":"2010","journal-title":"PLoS One"},{"key":"2022031303363917600_B7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.molmet.2012.11.003","article-title":"The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing","volume":"2","author":"Delaere","year":"2012","journal-title":"Mol Metab"},{"key":"2022031303363917600_B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031303363917600_B9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00592-018-1206-z","article-title":"The roots of SGLT inhibition: Laurent-Guillaume de Koninck, Jean Servais Stas and Freiherr Josef von Mering","volume":"56","author":"J\u00f6rgens","year":"2019","journal-title":"Acta Diabetol"},{"key":"2022031303363917600_B10","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"2022031303363917600_B11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI113157","article-title":"Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats","volume":"80","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"2022031303363917600_B12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI115031","article-title":"Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression","volume":"87","author":"Kahn","year":"1991","journal-title":"J Clin Invest"},{"key":"2022031303363917600_B13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI100618","article-title":"The effects on renal activity of the oral administration of phlorizin in man","volume":"13","author":"Goldring","year":"1934","journal-title":"J Clin Invest"},{"key":"2022031303363917600_B14","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","article-title":"Molecular analysis of the SGLT2 gene in patients with renal glucosuria","volume":"14","author":"Santer","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2022031303363917600_B15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031303363917600_B16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J Med Chem"},{"key":"2022031303363917600_B17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1479164114563304","article-title":"Development of sotagliflozin, a dual sodium-dependent glucose transporter 1\/2 inhibitor","volume":"12","author":"Lapuerta","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"2022031303363917600_B18","doi-asserted-by":"crossref","first-page":"e99123","DOI":"10.1172\/jci.insight.99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study","volume":"3","author":"Blau","year":"2018","journal-title":"JCI Insight"},{"key":"2022031303363917600_B19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2022031303363917600_B20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s12325-016-0457-8","article-title":"Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus","volume":"34","author":"Tanaka","year":"2017","journal-title":"Adv Ther"},{"key":"2022031303363917600_B21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031303363917600_B22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031303363917600_B23","doi-asserted-by":"crossref","first-page":"e84996","DOI":"10.1371\/journal.pone.0084996","article-title":"Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells","volume":"9","author":"Kimura","year":"2014","journal-title":"PLoS One"},{"key":"2022031303363917600_B24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"2022031303363917600_B25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1152\/ajplegacy.1944.142.5.648","article-title":"The renal reabsorptive mechanism for inorganic phosphate in normal and acidotic dogs","volume":"142","author":"Pitts","year":"1944","journal-title":"Am J Physiol"},{"key":"2022031303363917600_B26","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"key":"2022031303363917600_B27","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1185\/03007995.2014.919907","article-title":"Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)","volume":"30","author":"Weir","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2022031303363917600_B28","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF00281818","article-title":"Influence of glucagon on plasma levels of potassium in man","volume":"19","author":"Massara","year":"1980","journal-title":"Diabetologia"},{"key":"2022031303363917600_B29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031303363917600_B30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031303363917600_B31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"2022031303363917600_B32","doi-asserted-by":"crossref","first-page":"31214","DOI":"10.1038\/srep31214","article-title":"Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells","volume":"6","author":"Pedersen","year":"2016","journal-title":"Sci Rep"},{"key":"2022031303363917600_B33","first-page":"G1168","article-title":"Kinetic and molecular identification of sodium-dependent glucose transporter in normal rat cholangiocytes","volume":"272","author":"Lazaridis","year":"1997","journal-title":"Am J Physiol"},{"key":"2022031303363917600_B34","unstructured":"Sembrowich WL, Anderson CR, Kennedy WR, inventors. Method and apparatus for non-invasively monitoring plasma glucose levels. U.S. patent 5,036,861A. 6 August 1991"},{"key":"2022031303363917600_B35","doi-asserted-by":"crossref","first-page":"e0195960","DOI":"10.1371\/journal.pone.0195960","article-title":"Sweat glucose and GLUT2 expression in atopic dermatitis: implication for clinical manifestation and treatment","volume":"13","author":"Ono","year":"2018","journal-title":"PLoS One"},{"key":"2022031303363917600_B36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1124\/dmd.113.056440","article-title":"Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans","volume":"42","author":"Mamidi","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"2022031303363917600_B37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/jcph.506","article-title":"In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans","volume":"55","author":"Francke","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2022031303363917600_B38","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"2022031303363917600_B39","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"},{"key":"2022031303363917600_B40","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"H\u00e4ring","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/dom.13116","article-title":"Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study","volume":"20","author":"Dagogo-Jack","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031303363917600_B42","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/dom.12418","article-title":"Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study","volume":"17","author":"Sha","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031303363917600_B43","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031303363917600_B44","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B45","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"2022031303363917600_B46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.nutr.26.061505.111258","article-title":"Fuel metabolism in starvation","volume":"26","author":"Cahill","year":"2006","journal-title":"Annu Rev Nutr"},{"key":"2022031303363917600_B47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1475-2840-13-65","article-title":"Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study","volume":"13","author":"Kaku","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2022031303363917600_B48","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/jdi.12726","article-title":"Changes in heart rate in patients with type\u00a02 diabetes mellitus after treatment with luseogliflozin: subanalysis of placebo-controlled, double-blind clinical trials","volume":"9","author":"Sano","year":"2018","journal-title":"J Diabetes Investig"},{"key":"2022031303363917600_B49","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1479164115585298","article-title":"Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes","volume":"12","author":"Sj\u00f6str\u00f6m","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"2022031303363917600_B50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2022031303363917600_B51","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13300-018-0480-7","article-title":"Effect of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: rationale","volume":"9","author":"Kubota","year":"2018","journal-title":"Diabetes Ther"},{"key":"2022031303363917600_B52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12933-017-0532-8","article-title":"Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial","volume":"16","author":"Tanaka","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2022031303363917600_B53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031303363917600_B54","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2337\/dc13-0356","article-title":"Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE)","volume":"36","author":"Nathan","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B55","doi-asserted-by":"crossref","first-page":"e009326","DOI":"10.1161\/JAHA.118.009326","article-title":"Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT","volume":"7","author":"Beddhu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2022031303363917600_B56","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B57","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"2022031303363917600_B58","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.2337\/db13-1093","article-title":"Diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions","volume":"62","author":"Nathan","year":"2013","journal-title":"Diabetes"},{"key":"2022031303363917600_B59","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J Clin Med Res"},{"key":"2022031303363917600_B60","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.113.007071","article-title":"Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease","volume":"129","author":"Stanton","year":"2014","journal-title":"Circulation"},{"key":"2022031303363917600_B61","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2022031303363917600_B63","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B64","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031303363917600_B65","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B66","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B67","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B68","first-page":"967","article-title":"Effects of sotagliflozin added to insulin in type 1 diabetes","volume":"378","author":"Garg","year":"2018","journal-title":"N Engl J Med"},{"key":"2022031303363917600_B69","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031303363917600_B70","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B71","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B72","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031303363917600_B73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pds.932","article-title":"Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients","volume":"13","author":"Erkens","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022031303363917600_B74","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1472-8206.1998.tb00972.x","article-title":"Calcium antagonists and thiazide diuretics have opposite effects on blood rheology and radial artery compliance in arterial hypertension: a randomized double-blind study","volume":"12","author":"Khder","year":"1998","journal-title":"Fundam Clin Pharmacol"},{"key":"2022031303363917600_B75","first-page":"201","article-title":"Influence of a calcium antagonist on blood rheology and arterial compliance in hypertension: comparison with a thiazide diuretic","volume":"21","author":"Stoltz","year":"1999","journal-title":"Clin Hemorheol Microcirc"},{"key":"2022031303363917600_B76","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/193229680800200622","article-title":"Hemorheological disorders in diabetes mellitus","volume":"2","author":"Cho","year":"2008","journal-title":"J Diabetes Sci Technol"},{"key":"2022031303363917600_B77","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2174\/1381612054367328","article-title":"Microcirculation of the diabetic foot","volume":"11","author":"Dinh","year":"2005","journal-title":"Curr Pharm Des"},{"key":"2022031303363917600_B78","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031303363917600_B79","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2022031303363917600_B80","unstructured":"Kwon H. Canagliflozin: clinical efficacy and safety. Endocrinology and Metabolic Drugs Advisory Committee Meeting [Internet], 2013. Available from https:\/\/wayback.archive-it.org\/7993\/20170405220021\/https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM336234.pdf. Accessed on 8 July 2015"},{"key":"2022031303363917600_B81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031303363917600_B82","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","article-title":"Adverse effects of SGLT2 inhibitors on bone health","volume":"14","author":"Blau","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2022031303363917600_B83","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031303363917600_B84","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/diabetes.diabetesjournals.org\/syndication\/doi\/10.2337\/dbi18-0006","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/68\/6\/1109\/554115\/dbi180006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/68\/6\/1109\/554115\/dbi180006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:37:54Z","timestamp":1667407074000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/68\/6\/1109\/39722\/Sodium-Glucose-Cotransporter-2-Inhibitors-A-Case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,13]]},"references-count":84,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,5,13]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi18-0006","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,13]]}}}